INSM
Price:
$71.04
Market Cap:
$12.21B
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated ...[Read more]
Industry
Biotechnology
IPO Date
2000-06-01
Stock Exchange
NASDAQ
Ticker
INSM
According to Insmed Incorporated’s latest financial reports and current stock price. The company's current PE Ratio is -13.13. This represents a change of 97.79% compared to the average of -6.64 of the last 4 quarters.
The mean historical PE Ratio of Insmed Incorporated over the last ten years is -7.28. The current -13.13 PE Ratio has changed 17.92% with respect to the historical average. Over the past ten years (40 quarters), INSM's PE Ratio was at its highest in in the December 2018 quarter at -2.76. The PE Ratio was at its lowest in in the June 2015 quarter at -12.98.
Average
-7.28
Median
-7.48
Minimum
-11.05
Maximum
-3.11
Discovering the peaks and valleys of Insmed Incorporated PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 155.37%
Maximum Annual PE Ratio = -3.11
Minimum Annual Increase = -71.15%
Minimum Annual PE Ratio = -11.05
Year | PE Ratio | Change |
---|---|---|
2023 | -5.81 | 13.73% |
2022 | -5.11 | -27.34% |
2021 | -7.03 | -36.41% |
2020 | -11.05 | 39.16% |
2019 | -7.94 | 155.37% |
2018 | -3.11 | -71.15% |
2017 | -10.78 | 132.12% |
2016 | -4.64 | -48.34% |
2015 | -8.99 | 6.87% |
2014 | -8.41 | -20.72% |
The current PE Ratio of Insmed Incorporated (INSM) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-5.98
5-year avg
-7.39
10-year avg
-7.28
Insmed Incorporated’s PE Ratio is less than Ascendis Pharma A/S (-12.57), greater than Apellis Pharmaceuticals, Inc. (-15.28), greater than BeiGene, Ltd. (-38.25), less than Akero Therapeutics, Inc. (-8.95), greater than Blueprint Medicines Corporation (-26.44), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), greater than Avidity Biosciences, Inc. (-17.14), greater than Revolution Medicines, Inc. (-13.31), less than Day One Biopharmaceuticals, Inc. (-7.39), less than SpringWorks Therapeutics, Inc. (-9.54), less than Keros Therapeutics, Inc. (-11.28), greater than Janux Therapeutics, Inc. (-51.01), less than Fennec Pharmaceuticals Inc. (54.24), greater than Edgewise Therapeutics, Inc. (-14.14), less than Harmony Biosciences Holdings, Inc. (17.58), less than Halozyme Therapeutics, Inc. (22.31), less than Agios Pharmaceuticals, Inc. (-6.74), less than Ultragenyx Pharmaceutical Inc. (-8.17),
Company | PE Ratio | Market cap |
---|---|---|
-12.57 | $6.83B | |
-15.28 | $5.00B | |
-38.25 | $21.01B | |
-8.95 | $1.83B | |
-26.44 | $5.47B | |
-17.73 | $8.19B | |
-17.14 | $4.74B | |
-13.31 | $6.99B | |
-7.39 | $1.25B | |
-9.54 | $2.88B | |
-11.28 | $1.97B | |
-51.01 | $2.15B | |
54.24 | $144.76M | |
-14.14 | $1.64B | |
17.58 | $2.02B | |
22.31 | $7.50B | |
-6.74 | $2.46B | |
-8.17 | $5.09B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Insmed Incorporated using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Insmed Incorporated or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Insmed Incorporated's PE Ratio?
How is the PE Ratio calculated for Insmed Incorporated (INSM)?
What is the highest PE Ratio for Insmed Incorporated (INSM)?
What is the 3-year average PE Ratio for Insmed Incorporated (INSM)?
What is the 5-year average PE Ratio for Insmed Incorporated (INSM)?
How does the current PE Ratio for Insmed Incorporated (INSM) compare to its historical average?